June 23, 2020 / 5:21 AM / 20 days ago

BRIEF-Principia Biopharma: first patient enrolled in partner Sanofi’s Phase 3 clinical trial of SAR442168 in patients with relapsing multiple sclerosis (RMS).

PARIS, June 23 (Reuters) - Principia Biopharma/Sanofi:

* First patient has been enrolled in its partner Sanofi’s Phase 3 clinical trial of SAR442168 in patients with relapsing multiple sclerosis (RMS).

* Principia will be entitled to a $50 million milestone payment.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below